Lineage Q1 net loss $7.1M ($0.04/sh); cash $78.1M; pipeline expanded

Lineage Cell Therapeutics, Inc.

2022-Q1 EPS reported -$0.04 revenue$5,237,000

Net loss attributable to Lineage of $7.1M ($0.04/sh) vs $1.4M ($0.01/sh) in Q1 2021.
Total revenues $5.2M, up from $0.4M YoY, driven by $50M Roche upfront licensing fee.
Cash and cash equivalents $78.1M as of March 31, 2022.
Pipeline expanded with two new cell therapy programs: auditory neurons (ANP1) and photoreceptors (PNC1).
VAC2 Phase 1 NSCLC enrollment completed; IND submission for US testing expected 2H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.